Patents Examined by Ronald Schwadron
-
Patent number: 8449922Abstract: A method for treating a chemically sensitive individual is provided. The method includes the steps of: collecting a blood sample from the individual; isolating normal mixed T and B lymphocytes from the blood sample; propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes; lysing the propagated lymphocytes to obtain a lysate; and administering the lysate to the individual. A therapeutic dose of the lysate can be determined by skin testing, and the dose can be administered subcutaneously. The effects of the treatment on the individual can be reflected by clinical tests such as hematological immunological profiles and symptom and signs scores.Type: GrantFiled: July 30, 1997Date of Patent: May 28, 2013Inventors: William James Rea, Bertie B. Griffiths
-
Patent number: 8435520Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.Type: GrantFiled: February 11, 2011Date of Patent: May 7, 2013Inventors: Hendrik J. Schuurman, Emanuele Luigi Maria Cozzi, Francoise Richard, Guy Taccard, David James Graham White, Peter John Friend, John Wallwork, Paolo Brenner
-
Patent number: 8337844Abstract: A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.Type: GrantFiled: March 28, 2012Date of Patent: December 25, 2012Assignee: Merck Patent GmbHInventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
-
Patent number: 8329181Abstract: The present invention provides methods for treating a B-cell lymphoma in a human subject. The methods of the invention comprise administering to a subject in need thereof an antibody or antigen-binding fragment thereof that specifically binds human CD20. In certain embodiments, the methods of the invention are useful for treating non-Hodgkin's B-cell lymphoma.Type: GrantFiled: December 13, 2011Date of Patent: December 11, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
-
Patent number: 8329172Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.Type: GrantFiled: August 18, 2007Date of Patent: December 11, 2012Assignee: Biogen IdecInventor: Antonio J. Grillo-López
-
Patent number: 8323653Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.Type: GrantFiled: September 7, 2007Date of Patent: December 4, 2012Assignee: MedImmune, LLCInventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
-
Patent number: 8216581Abstract: The present invention relates to novel methods of identifying and producing an anti-platelet autoantibody. More preferably, the invention relates to identification and production of a human monoclonal anti-platelet autoantibody. Moreover, the invention relates to methods for treating or alleviating a disease, disorder or condition mediated by an anti-platelet autoantibody specifically binding with a platelet, or a component thereof, such as, but not limited to, idiopathic thrombocytopenic purpura, among others. Preferably, the antibody is an unglycosylated H44L4 Fab.Type: GrantFiled: December 23, 2004Date of Patent: July 10, 2012Assignee: The Trustees of the University of PennsylvaniaInventor: Donald L. Siegel
-
Patent number: 8178098Abstract: Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.Type: GrantFiled: April 3, 2001Date of Patent: May 15, 2012Assignee: National Jewish HealthInventors: Michael F. Lahn, Willi K. Born, Arihiko Kanehiro, Erwin Gelfand
-
Patent number: 8163522Abstract: The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.Type: GrantFiled: May 19, 1995Date of Patent: April 24, 2012Assignee: Hoffman-LaRoche Inc.Inventors: Manfred Brockhaus, Reiner Gentz, Dembic Zlatko, Werner Lesslauer, Hansruedi Lotscher, Ernst-Jurgen Schlaeger
-
Patent number: 8153125Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: May 20, 2004Date of Patent: April 10, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Jeffry D. Watkins, Julian Davies, David M. Marquis, Barrett W Allan, Brian Ondek
-
Patent number: 8147832Abstract: A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.Type: GrantFiled: August 13, 2004Date of Patent: April 3, 2012Assignee: Merck Patent GmbHInventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
-
Patent number: 8138323Abstract: An isolated DNA molecule has the sequence of encoding a fragment of encoding Tumor Necrosis Factor (TNF) Binding Protein II. It has a length sufficient to serve as an immunogen for raising antibodies against a polypeptide that is a fragment of TNF Binding Protein II. The DNA may be used to produce replicable expression vehicles and prokaryotic or eukaryotic expression host cells. Such host cells may be used to produce polypeptides encoded by such DNA molecules.Type: GrantFiled: December 16, 2002Date of Patent: March 20, 2012Assignee: Yeda Research and Development Co., Ltd.Inventors: David Wallach, Hartmut Engelmann, Dan Aderka, Daniela Novick, Menachem Rubinstein
-
Patent number: 8133744Abstract: A method of making antibodies to a selected part P of an immunoglobulin molecule ZP, Z comprising the non-selected part of ZP, P being the selected part of ZP which comprises a hidden epitope of the light chain, said method comprises tolerizing the source of antibodies, by administering to the source a compound containing the non-selected part Z or a part of Z and administering antibodies to the non-selected part Z or a part of Z; wherein these administered antibodies are specific to an Fc region of ZP; and immunizing the source of antibodies with part of ZP having the selected part P exposed; and wherein Z comprises non-hidden epitopes of said immunoglobulin molecule, and wherein said compound containing the non-selected part of said molecule comprises a whole immunoglobulin, and wherein immunizing the source of antibodies with part of ZP comprises immunizing with free light chain.Type: GrantFiled: October 31, 1996Date of Patent: March 13, 2012Assignee: The Binding Site Group LimitedInventor: Arthur Randell Bradwell
-
Patent number: 8101179Abstract: A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.Type: GrantFiled: March 31, 2006Date of Patent: January 24, 2012Assignee: Biomedics Inc.Inventors: Masanori Numazaki, Tetsuo Nakamura, Sadakazu Usuda, Eduardo A. Padlan
-
Patent number: 8097713Abstract: The present invention provides nucleic acid molecules which encode human antibodies or antigen-binding fragments thereof that specifically bind human CD20. Also provided are expression vectors comprising nucleic acid molecules that encode anti-CD20 antibodies, and methods of producing anti-human CD20 antibodies or antigen-binding fragments thereof.Type: GrantFiled: December 13, 2010Date of Patent: January 17, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
-
Patent number: 8088378Abstract: The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: July 15, 2008Date of Patent: January 3, 2012Assignee: Genetech Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8067229Abstract: The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.Type: GrantFiled: November 3, 2005Date of Patent: November 29, 2011Assignee: Genentech, Inc.Inventors: Sean Adams, James Pan, Alan Zhong
-
Patent number: 8067361Abstract: The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly advantageous form treatment of both the donor and recipient animal. The method may further include the administration to the donor and/or recipient animal at least one other immunosuppressive agent to prevent or alleviate graft versus host disease.Type: GrantFiled: October 1, 2009Date of Patent: November 29, 2011Assignee: CBIO LimitedInventors: Geoffrey R. Hill, Tatjana Banovic, Halle Morton, Alice Christina Cavanagh
-
Patent number: 8034332Abstract: This invention relates to a natural killer cell line termed NK-92 and to NK-92 cell lines that have been modified by transfection with a vector to confer advantageous properties. The invention provides a modified NK-92 cell line that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. In a significant embodiment, the cytokine is interleukin 2. The invention additionally provides a modified NK-92 cell line that is transfected with a vector that expresses a thymidine kinase gene. The invention further provides a modified NK-92 cell line that is transfected with a vector that expresses a ?2 micrglobulin.Type: GrantFiled: June 6, 2003Date of Patent: October 11, 2011Assignee: Conkwest, Inc.Inventor: Hans Klingemann
-
Patent number: 7988972Abstract: The Epstein-Barr virus (EBV) specific polypeptides ETFTETWNRFITHTE (SEQ. ID NO: 1), GMLEASEGLDGWIHQ (SEQ. ID NO:2), HQQGGWSTLIEDNIP (SEQ. ID NO:3), and KQKHPKKVKQAFNPL (SEQ. ID NO:4) are among those disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.Type: GrantFiled: December 14, 2007Date of Patent: August 2, 2011Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Richard S. Smith, Gary R. Pearson, D. Elliot Parks, Susan Pothen Varghese